GlaxoSmithKline Consumer Healthcare Investments (Ireland) (No.2) Limited v Apotex Pty Ltd

GlaxoSmithKline Consumer Healthcare Investments (Ireland) (No.2) Limited (GSK) brought proceedings against Apotex Pty Ltd (Apotex) and several other defendants, seeking relief for patent infringement and breach of confidence in relation to pharmaceutical products. The dispute involved allegations that Apotex infringed GSK's patents by manufacturing and selling generic versions of GSK's products and disclosing confidential information. The case was heard in the Federal Court of Australia.

The legal issues before the court included whether GSK had established a prima facie case of patent infringement and breach of confidence, and whether Apotex had demonstrated sufficient grounds to be released from undertakings previously given to GSK. The court had to determine whether the balance of convenience favoured Apotex in discharging the undertakings and whether Apotex should be granted leave to amend its undertakings. The court also needed to consider the appropriate form of relief, including whether to leave the undertakings in place or replace them with injunctions.

In dismissing Apotex's applications, the court found that GSK had established a prima facie case of patent infringement and breach of confidence. The court held that the balance of convenience favoured GSK in maintaining the existing restraints, despite the forensic difficulties in proving quantum of losses on both sides. The court noted that even if Apotex had demonstrated a greater risk of prejudice, this would not have tipped the balance in Apotex's favour. Therefore, the court determined that the existing restraints should remain in place. The court allowed Apotex leave to amend its undertakings to more accurately reflect the steps required to comply with the court's orders.

The court dismissed Apotex's interlocutory applications and ordered that the costs of the parties in relation to the interlocutory application be costs in the cause. The court also ordered variations to Apotex's undertakings to ensure clarity and compliance with the court's directions. The court will hear further submissions from the parties on any questions of costs and further variations to the undertakings.